MedTrace Logo

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT03552471 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-02-13

No results posted yet for this study

Summary

This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and rucaparib camsylate in treating participants with endometrial, ovarian, fallopian tube or primary peritoneal cancer that has come back. Drugs such as mirvetuximab soravtansine are antibodies linked to a toxic substance and may help find certain tumor cells and kill them without harming normal cells. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving mirvetuximab soravtansine and rucaparib camsylate may work better in treating participants with recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer.

Conditions

  • BRCA1 Gene Mutation
  • BRCA2 Gene Mutation
  • Folate Receptor Alpha Positive
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Primary Peritoneal Carcinoma
  • Recurrent Uterine Corpus Carcinoma
  • Recurrent Uterine Serous Carcinoma
  • Recurrent Uterine Carcinosarcoma
  • Platinum Resistant Ovarian Cancer

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Mirvetuximab Soravtansine

Given IV

OTHER

Pharmacokinetic Study

Correlative studies

DRUG

Rucaparib Camsylate

Given PO

Sponsors & Collaborators

  • ImmunoGen, Inc.

    collaborator INDUSTRY

  • Clovis Oncology, Inc.

    collaborator INDUSTRY

  • Ohio State University Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Floor Backes, MD · Ohio State University Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-12
Primary Completion
2022-06-24
Completion
2022-12-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03552471 on ClinicalTrials.gov